Photodynamic Therapy Market

Healthcare Providers Increase their Efficacy in Photodynamic Therapy for Breast Cancer Resistance

New discoveries in photodynamic therapy (PDT) are benefitting cancer patients. As such, it has been found that, PDT is effective in treating multidrug-resistant breast cancer. Dysfunctional DNA repair genes and abnormal signal transduction are some of the major complications associated with breast cancer resistance. Hence, companies in the photodynamic therapy market are becoming increasingly aware about the complications of breast cancer resistance, and increasing the availability of PDT in hospitals and cancer treatment centers.

Cancer is projected to account for the highest revenue amongst all applications in the photodynamic therapy market, with an estimated value of ~US$ 2.3 billion by the end of 2023. This is why, healthcare companies are increasing awareness about PDT amongst breast cancer resistant patients. As such, PDT is being used as an alternative to broad-spectrum antibiotics-based therapy, thus minimizing the incidence of drug resistance. Companies are also increasing R&D to assess PDT-resistant cells to further study the impact of PDT on cellular targets. Healthcare providers are increasing their efficacy in PDT technology to achieve therapeutic relevance in appropriate photosensitizer (PS) level with its retention in the target tissue.

To know the scope of our report Get a Sample on Photodynamic Therapy Market

Dermoscopy Aids in Assessment of ALA Drugs Effective for AK Treatment

Growing incidence of actinic keratosis (AK) have led to innovations in the photodynamic therapy market. Dermoscopy serves as a useful tool for monitoring skin lesions during PDT and follow-up. Healthcare providers in the photodynamic therapy landscape are treating actinic keratosis (AK) patients with aminolevulinic acid (ALA) drugs. ALA agents are increasingly gaining popularity, and are anticipated to account for the highest revenue amongst all drugs in the photodynamic therapy market, with a projected value of ~US$ 4 billion by the end of 2027. Thus, healthcare providers in hospitals and dermatology clinics are offering topical ALA-PDT, since the treatment is widely approved by health commissions across various countries.

Dermoscopic monitoring is being used in tandem with PDT, and serves as a valuable and non-invasive technique, not just for diagnosing AK but also other serious skin diseases. The technique of dermoscopy is very useful for healthcare providers, since it can visualize the morphological structures of the inner layers of the skin that are not visible to the naked eye. Thus, dermoscopy is boosting the growth of the photodynamic therapy market.

Get a glimpse of the in-depth analysis through our Report Brochure

Customized Protocol Strategies Deliver Enhanced Clinical Translation

Healthcare providers in the photodynamic therapy market are adopting new strategies to achieve enhanced clinical translation. They are using the approach of customized protocols for the treatment of cancer and other infectious diseases. Companies are developing improved formulations of porphyrin-derivative (PD) compounds. This trend is projected to grow during the forecast period, since PD is projected to account for the second-highest revenue amongst all drugs in the photodynamic therapy market, with an estimated value of ~US$ 3 billion by the end of 2027. Hence, companies are developing intelligent PD molecules that can target specific cells and offer efficient drug delivery.

Companies in the photodynamic therapy market are developing strategies to improve transdermal ALA delivery. They are utilizing high-power CO2 lasers to produce microhole grating. Companies are increasing the production of ALA creams, since the grating procedure is followed by the application of the cream, assisted by ultrasound, to enhance the cream’s penetration into the holes. Another approach, such as the use of a soluble microneedle patch, helps in continuous delivery of ALA until the material is completely dissolved inside the lesion.

Innovative Photodynamic Devices Show the Way for Exponential Growth in Cancer Treatment

The photodynamic therapy and light-based therapy market are maturing at a rapid pace. However, prevailing challenges catering to the delivery of light to the right body part with adequate strength and specificity are likely to impede market growth. Another challenge is that, the photodynamic therapy market is highly consolidated, with only three market players accounting for ~90% of the market share. This makes it challenging for medium- and small-scale players to compete with these major players in the landscape.

In order to overcome the challenges of light delivery, companies are increasing their production capabilities to improve the efficacy of novel delivery systems in photodynamic therapy. To achieve the intended therapeutic effect on the target, small- and medium-scale players are increasing R&D to develop wirelessly-powered light-emitting devices that improve the specificity of light-based cancer therapy. Innovations in devices have facilitated the treatment for hard-to-detect microtumors and deeply-located lesions. Photodynamic devices are increasingly meeting the needs of cancer patients due to the availability of devices that do not require surgical suturing.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Phosistos protocol involving new light-emitting devices are gaining popularity for the effective treatment of actinic keratosis. Companies in the photodynamic therapy market are also gaining a strong hold though inorganic strategies such as label extensions. For instance, in September 2019, Biofrontera - a leading biopharmaceutical company, announced label extension for Ameluz^(R)  - an ALA used for the treatment of mild and moderate actinic keratosis in PDT.

However, prevalent challenges in drug-resistant breast cancer treatment, such as blood vessel occlusion, collapse, and ultimate vascular shutdown, pose as a challenge in PDT. Thus, companies should increase research efforts to evaluate the advantages of photochemical internalization to facilitate the cytosolic delivery of macromolecular drugs to combat multidrug-resistant breast cancer.